Physician profile
Javier A Jover
NPI 1659449304
$15,145.59
in general payments reported to CMS, 2019-2025
28 companies · $823 in 2025
The $823 reported for 2025 was more than what 75% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,562 · 2020: $3,078 · 2021: $251 · 2022: $271 · 2023: $233 · 2024: $4,927 · 2025: $823.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,420 · Food and Beverage: $1,303 · Consulting Fee: $200 · Education: $59.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,419.87 |
| Food and Beverage | $1,303.05 |
| Consulting Fee | $200.00 |
| Education | $59.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $5,264.48 | 2019-2020 | |
| Olympus Corporation of The Americas | $2,351.15 | 2024-2025 | |
| Pinnacle Biologics, INC | $2,022.13 | 2019 | |
| Medtronic, INC. | $1,756.14 | 2024 | Illumisite |
| Abiomed | $644.27 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $353.78 | 2019-2024 | Lynparza |
| Actelion Pharmaceuticals US, INC. | $343.82 | 2019-2024 | Uptravi, Opsumit |
| Intuitive Surgical, INC. | $335.63 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $280.71 | 2022-2024 | Reblozyl |
| Sunovion Pharmaceuticals INC. | $227.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $200.00 | 2024 | |
| Janssen Biotech, INC. | $156.99 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $144.45 | 2019-2023 | Breztri |
| Novo Nordisk INC | $139.89 | 2021 | |
| Boston Scientific Corporation | $128.70 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $123.25 | 2025 | Cabometyx |
| Jazz Pharmaceuticals INC. | $102.00 | 2020 | |
| Intercept Pharmaceuticals, INC. | $100.26 | 2019 | |
| Amgen INC. | $93.10 | 2019 | |
| Amarin Pharma, INC. | $92.43 | 2019 | |
| Fisher & Paykel Healthcare INC | $78.56 | 2024 | Fisher & Paykel Healthcare |
| La Jolla Pharmaceutical Company | $66.67 | 2023 | Giapreza |
| Genentech USA, INC. | $39.95 | 2019 | |
| United Therapeutics Corporation | $25.36 | 2021-2023 | Tyvaso |
| Vapotherm INC | $24.30 | 2020 | |
| Baxter Healthcare | $20.61 | 2023 | Hillrom - Life 2000 Ventilation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.47 | 2020 | |
| Glaxosmithkline, LLC. | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Javier Jover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.